VJHemOnc

@VJHemOnc

The Video Journal of Hematology & Hematological Oncology is dedicated to providing up-to-date information & international expertise

Joined April 2015

5KFollowing

21KFollowers

Pinned

VJHemOnc@VJHemOnc · Jul 20

🎥 @DrPinkalDesai of @WeillCornell discusses healthcare resource utilization in newly diagnosed patients with AML treated with venetoclax compared with high- or low-intensity non-venetoclax therapies: 👉 ow.ly/QWqp50WrI3e 👈 #AMLsm #Leusm #Leukemia #HemOnc #EHA2025

VJHemOnc's tweet card. Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses healthcare resource utilization in newly diagnosed patients with acute myeloid leukemia (AML) treated with venetoclax compared...

526

VJHemOnc@VJHemOnc · 3 h

#18ICML | Neil Berinstein of @Sunnybrook shares updates from the BRAWM trial, which is evaluating the combination of bendamustine, rituximab, & acalabrutinib in Waldenström’s macroglobulinemia: 🎥 ow.ly/V8By50WtM94 #LYMsm #Lymphoma #RareDisease #HemOnc #ImmunoOnc #CTSM…

VJHemOnc's tweet card. Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, shares the promising results of the BRAWM trial (NCT04624906), which is evaluating the combination of bendamustine, rituximab,...

210

VJHemOnc@VJHemOnc · 17 h

Want to hear insights into the real-world effectiveness of covalent BTK inhibitors in the first-line treatment of patients with symptomatic CLL?🩸 Check out our fantastic recent interview from #18ICML with Ryan Jacobs (@LevineCancer): 👉 ow.ly/hLWf50WtM6o 👈 #CLLsm…

VJHemOnc's tweet card. Ryan Jacobs, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC, shares insights into the real-world effectiveness of covalent BTK inhibitors in...

378

VJHemOnc@VJHemOnc · Jul 26

It was wonderful to catch up with @MosqueraOrgeira at iwMDS/MPN 2025 to learn about the application of AI-driven models into clinical practice in MDS & MPNs!🩸 Click here for the interview: 🎥 ow.ly/34ww50WtMA5 #iwMDS25 #iwMPN25 #AI #AIinHemOnc #HemOnc #MDSsm #MPNsm

VJHemOnc's tweet card. Adrián Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, discusses the possible applications of artificial intelligence (AI) methods in the diagnosis and risk stratification...

397

VJHemOnc@VJHemOnc · Jul 25

🎥 Robert Sidonio Jr. (@EmoryMedicine) shares insight into a Phase III study evaluating the safety, immunogenicity, & hemostatic efficacy of rurioctocog alfa pegol in previously untreated patients (PUPs) with severe #hemophilia A: 👉 ow.ly/3O5g50WtNtY 👈 #ISTH2025…

VJHemOnc's tweet card. In this interview, Robert Sidonio Jr., MD, Emory School of Medicine, Atlanta, GA, discusses a Phase III study (NCT02615691) evaluating the safety, immunogenicity, and hemostatic efficacy of rurioct...

352

VJHemOnc@VJHemOnc · Jul 25

Hear as @elizabeth_budde of @cityofhope shares the promising results of a Phase II study evaluating mosunetuzumab plus polatuzumab vedotin in pts with R/R #MantleCellLymphoma & high-risk features. Click here: 🎥 ow.ly/Qbm450WtM2c #LYMsm #18ICML #CTSM #TrialUpdate…

VJHemOnc's tweet card. Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, discusses the promising results of a Phase II study evaluating the combination of mosunetuzumab and polatuzumab vedotin in patients with relapsed...

364

VJHemOnc@VJHemOnc · Jul 24

Following #18ICML, we had the pleasure of catching up with @NGhoshMD of @LevineCancer to hear his highlights in #NonHodgkinLymphoma from this year’s meeting.🩸 Click here for the comprehensive overview: 👉 ow.ly/1rZ850WtLZG #DLBCL #MantleCellLymphoma #FollicularLymphoma…

VJHemOnc's tweet card. Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, shares his highlights in non-Hodgkin lymphoma (NHL) from this year's ICML meeting. Dr Ghosh first discusses key advances in frontline...

428

VJHemOnc@VJHemOnc · Jul 24

We recently caught up with Farhad Ravandi of @MDAndersonNews, who spoke on the current standard of treatment for older or unfit patients with AML and outlined future directions in this patient population. Watch here: 🎥 ow.ly/ACmC50WtNEb #AMLsm #Leusm #Leukemia #HemOnc…

VJHemOnc's tweet card. Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the current standard of treatment for older or unfit patients with acute myeloid leukemia (AML). He...

352

VJHemOnc@VJHemOnc · Jul 23

🎥 Shaji Kumar (@myelomaMD) of @MayoClinic discusses the safety & efficacy of talquetamab & teclistamab in patients with R/R #MultipleMyeloma and EMD, highlighting findings from the RedirecTT-1 study: 👉 ow.ly/5nGo50WrJSU 👈 #MMSM #Myeloma #HemOnc #CTSM #TrialUpdate…

VJHemOnc's tweet card. Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses results from a cohort of the RedirecTT-1 study (NCT04586426), investigating the safety and efficacy of combining talquetamab and teclistamab in...

431

VJHemOnc@VJHemOnc · Jul 23

Listened to our most recent podcast?🎙️ #iwMDS25 recently took place, bringing together the world’s leading clinical researchers in MDS & MPNs to share their perspectives on how to place our evolving understanding in a clinical context and optimize clinical care. 🎧Listen here:…

VJHemOnc's tweet image. Listened to our most recent podcast?🎙️

#iwMDS25 recently took place, bringing together the world’s leading clinical researchers in MDS &amp; MPNs to share their perspectives on how to place our evolving understanding in a clinical context and optimize clinical care.

🎧Listen here:…

763

VJHemOnc@VJHemOnc · Jul 23

In an interview from #18ICML, @NikMankuzhy of @MSKCancerCenter provides insight into the efficacy of response-adapted very low-dose radiotherapy at a dose of 4 Gy for indolent #NonHodgkinLymphoma: 🎥 ow.ly/p8u350WjwPN #LYMsm #Lymphoma #RadOnc #HemOnc

VJHemOnc's tweet card. In this interview, Nikhil Mankuzhy, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, provides insight into the efficacy of response-adapted very low-dose radiotherapy at a dose of 4...

740

VJHemOnc@VJHemOnc · Jul 22

The PhII EpLCART trial is assessing the feasibility of ctDNA-directed epcoritamab with/without R-squared in pts with LBCL at high risk of relapse in the early post-CAR-T setting. Hear more from @markrdowling of @PeterMacCC: 🎥 ow.ly/K6cA50Wjw89 #LYMsm #CTSM #ImmunoOnc

VJHemOnc's tweet card. Mark Dowling, MBBS, PhD, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia, provides insight into the Phase II EpLCART trial (NCT06414148), a study assessing the...

555

VJHemOnc@VJHemOnc · Jul 22

Watch our recent interview with @jaeparkmd of @MSKCancerCenter to hear about the long-term data with obe-cel in ALL & its potential to serve as a standalone treatment for adult R/R B-ALL. Click here: 👉 ow.ly/t0i450WrIbE #ALLsm #Leusm #Leukemia #CTSM #CARTCell #ImmunoOnc…

VJHemOnc's tweet card. Jae Park, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses long-term data on obecabtagene autoleucel (obe-cel) and its potential to serve as a standalone treatment for adult...

453

VJHemOnc@VJHemOnc · Jul 21

The MPN Workshop of the Carolinas aims to provide up-to-date information about the pathogenesis & management of MPNs to practicing clinicians & to foster discussion to improve outcomes for patients.🩸 Register for the in-person event or the webinar here: 👉…

VJHemOnc's tweet image. The MPN Workshop of the Carolinas aims to provide up-to-date information about the pathogenesis &amp; management of MPNs to practicing clinicians &amp; to foster discussion to improve outcomes for patients.🩸

Register for the in-person event or the webinar here:
👉…

754

VJHemOnc@VJHemOnc · Jul 21

Welcome to The #Lymphoma Sessions brought to you by #VJHemOnc 💬 🩸 🎥 This exclusive discussion features leading #lymphoma experts @KrishPatelMD, @LymphClinician and Craig Portell, who discuss the value of #BTKinhibitors in frontline and relapsed #MCL They cover a variety of…

456

VJHemOnc@VJHemOnc · Jul 21

Want to hear about updates & advances in MDS classification & risk stratification?🩸 Watch our fantastic roundtable discussion from #iwMDS25 with experts @beatalleukemia, Luca Lanino, Robert Hasserjian, & @ZhuoerXie: 🎥 ow.ly/h1iJ50WrHmq #MDSsm #HemOnc

VJHemOnc's tweet card. In this discussion, Uma Borate, MD, The Ohio State University, Columbus, OH, Luca Lanino, MD, PhD, Yale University, New Haven, CT, Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA,...

1.0K

VJHemOnc@VJHemOnc · Jul 20

🎥 @YucaiWangMD of @MayoClinic discusses how to select between covalent and non-covalent BTK inhibitors when treating patients with #MantleCellLymphoma: 👉 ow.ly/hXO150WjvQI 👈 #LYMsm #Lymphoma #18ICML #ICML2025 #NonHodgkinLymphoma #HemOnc

VJHemOnc's tweet card. In this video, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discusses how to select between covalent and non-covalent BTK inhibitors (BTKis) when treating patients with mantle cell lymphoma...

569

VJHemOnc@VJHemOnc · Jul 19

What are some of the most exciting developments in the field of Waldenström’s macroglobulinemia?🩸 We caught up with Steven Treon of @DanaFarber at #18ICML to find out! Watch the interview here: 👉 ow.ly/kqI950WjwAp 👈 #LYMsm #Lymphoma #HemOnc

VJHemOnc's tweet card. Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses recent developments in Waldenström’s macroglobulinemia, highlighting progress with newer agents, including non-covalent BTK...

609

VJHemOnc@VJHemOnc · Jul 19

#iwMPN25 | Alexander Lyon of @RBandH discusses cardiovascular health in patients with MPNs, and provides insight into risk stratification & management strategies.🫀🩸 Click here to watch the interview: 👉 ow.ly/FbjM50WrHwz 👈 #MPNsm #HemOnc

VJHemOnc's tweet card. Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA, Royal Brompton Hospital, London, UK, discusses cardiovascular health in patients with myeloproliferative neoplasms (MPNs), emphasizing the importance of...

525

VJHemOnc@VJHemOnc · Jul 18

In a fantastic discussion at #iwCART25 earlier this year, experts David Miklos, @DrFredLocke, @LazarosLekakis, & Sarah Nikiforow shared insights into the application of cell therapy to autoimmune diseases. Click here to watch: 👉 ow.ly/gKHm50WjzxJ 👈 #Hematology #CARTCell

VJHemOnc's tweet card. David Miklos, MD, PhD, Stanford University, Stanford, CA, chairs a roundtable discussion, in which he is joined by Frederick Locke, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL,...

395